AR057409A1 - Heterociclos oxigenados como moduladores de receptores de progesterona. composiciones farmaceuticas. - Google Patents
Heterociclos oxigenados como moduladores de receptores de progesterona. composiciones farmaceuticas.Info
- Publication number
- AR057409A1 AR057409A1 ARP060102752A ARP060102752A AR057409A1 AR 057409 A1 AR057409 A1 AR 057409A1 AR P060102752 A ARP060102752 A AR P060102752A AR P060102752 A ARP060102752 A AR P060102752A AR 057409 A1 AR057409 A1 AR 057409A1
- Authority
- AR
- Argentina
- Prior art keywords
- nrcrd
- alkyl
- alkenyl
- atom
- alkynyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 title 1
- 239000001301 oxygen Substances 0.000 title 1
- 102000003998 progesterone receptors Human genes 0.000 title 1
- 108090000468 progesterone receptors Proteins 0.000 title 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000004429 atom Chemical group 0.000 abstract 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 5
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 3
- 150000003254 radicals Chemical class 0.000 abstract 3
- 125000006413 ring segment Chemical group 0.000 abstract 3
- 229920001774 Perfluoroether Polymers 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- -1 C2- alkynyl 8 Chemical group 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000347391 Umbrina cirrosa Species 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000005418 aryl aryl group Chemical group 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000007954 uterine fibroid Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
Abstract
Su uso para la peparacion de medicamentos, así como a las composiciones farmacéuticas que contienen estos compuestos. Los compuestos segun la presente son apropiados para la terapia y la prevencion de enfermedades ginecologicas tales como endometriosis, leiomiomas de utero, hemorragias disfuncionales y dismenorrea y para la terapia y la prevencion de tumores dependientes de hormonas y para el uso para el control de la fertilidad femenina y para la terapia de reemplazo hormonal. Reivindicacion 1: Compuestos de la formula general (1) en donde R1 y R2 son, de modo independiente entre sí, un átomo de H, alquilo C1-5 lineal o no lineal, ramificado o no ramificado, que además forma junto con el átomo de C de la cadena un anillo con un total de 3-7 miembros, R3 es un radical C:::C-Ra, en donde Ra es un átomo de H o alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10, heterocicloalquilo eventualmente mono- o polisustituido, igual o diferente, con K o un arilo o heteroarilo eventualmente mono- o polisustituido, igual o diferente, con L, K es ciano, halogeno, hidroxi, nitro, -C(O)Rb, CO2Rb, -O-Rb, -S-Rb, SO2NRcRd, -C(O)-NRcRd, -OC(O)-NRcRd, -C=NORb-NRcRd o un cicloalquilo C3-10, heterocicloalquilo eventualmente mono- o polisustituido, igual o diferente, con M o arilo o heteroarilo eventualmente mono- o polisustituido con L; L es alquilo C1-8, alquenilo C2-8, alquinilo C2-8, perfluoroalquilo C1-6, perfluoroalcoxi C1-6, alcoxi C1-6-alcoxi C1-6, (CH2)p-cicloalquilo 3-10, (CH2)p-heterocicloalquilo, (CH2)pCN, (CH2)pHal, (CH2)pNO2, (CH2)p-arilo C6-12, (CH2)p-heteroarilo, -(CH2)p-PO3(Rb)2, -(CH2)p-NRcRd, -(CH2)p-NReCORb, -(CH2)p-NReCSRb, -(CH2)p-NReS(O)Rb, -(CH2)p-NReS(O)2Rb, -(CH2)p- NReCONRcRd, -(CH2)p-NReCOORb, -(CH2)p-NReC(NH)NRcRd, -(CH2)p-NReCSNRcRd, -(CH2)p-NReS(O)NRcRd, -(CH2)p-NReS(O)2NRcRd, -(CH2)p-CORb, -(CH2)p-CSRb, -(CH2)p-S(O)Rb, -(CH2)p-S(O)(NH)Rb, -(CH2)p-S(O)2Rb, -(CH2)p-S(O)2NRcRd, -(CH2)p-SO2ORb, -(CH2)p-CO2Rb, -(CH2)p-CONRcRd, -(CH2)p-CSNRcRd, -(CH2)p-ORb, -(CH2)p-SRb, -(CH2)p-CRb(OH)-Re, -(CH2)p-C=NORb, -O-(CH2)n-O-, -O-(CH2)n-CH2-, -O-CH=CH- o -(CH2)n+2-, en donde es n = 1 o 2 y los átomos de O y/o átomos de C terminales están unidos con átomos de C del anillo directamente adyacentes, M es alquilo C1-6 o un grupo -CORb, CO2Rb, -O-Rb o -NRcRd, en donde Rb es un átomo de H o un alquilo C1-6, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10, arilo C6-12 o perfluoroalquilo C1-3 y Rc y Rd son, de modo independiente entre sí, un átomo de H, alquilo C1-6, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10, arilo C6-12, C(O)Rb o un grupo hidroxi, en donde cuando Rc es un grupo hidroxi, Rd solo puede ser un átomo de H, un alquilo C1-6, alquenilo C2- 8, alquinilo C2-8, cicloalquilo C3-10 o arilo C6-12 y viceversa, así como Re es un átomo de H, alquilo C1-6, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10 o arilo C6-12 y p puede ser una cifra de 0 a 6, o R3 es un radical C=C-RgRh, en donde Rg y Rh son, de modo independiente o un alquilo C1-8, alquenilo C2-8 o alquinilo C2-8 eventualmente mono-o polisustituido, igual o diferente, con X en donde X es un ciano, halogeno, hidroxi, nitro, -C(O)Rb, CO2Rb, -O-Rb, -C(O)-NRcRd, -NRcRd con los significados ya mencionados más arriba para Rb, Rc y Rd y R4a y R4b son, de modo independiente entre sí, un átomo de H, un alquilo C1-4, un alquenilo C2-4 o forman, junto con el átomo de C del anillo, un anillo de 3-6 miembros, A es un anillo aromático carbocíclico o heterocíclico mono- o polisustituido con alquilo C1-8, alquenilo C2-8, alquinilo C2-8, perfluoroalquilo C1-6, perfluoroalcoxi C1-6, alcoxi C1-6-alquilo C1-6, alcoxi C1-6-alcoxi C1-6, (CH2)p-cicloalquilo C3-10, (CH2)p- heterocicloalquilo, (CH2)pCN, (CH2)pHal, (CH2)pNO2, (CH2)p-arilo C6-12, (CH2)p-heteroarilo, -(CH2)p-PO3(Rb)2, -(CH2)p-NRcRd, -(CH2)p-NReCORb, -(CH2)p-NReCSRb, -(CH2)p-NReS(O)Rb, -(CH2)p-NReS(O)2Rb, -(CH2)p-NReCONRcRd, -(CH2)p-NReCOORb, -(CH2)p- NReC(NH)NRcRd, -(CH2)p-NReCSNRcRd, -(CH2)p-NReS(O)NRcRd, -(CH2)p-NReS(O)2NRcRd, -(CH2)p-CORb, -(CH2)p-CSRb, -(CH2)p-S(O)Rb, -(CH2)p-S(O)(NH)Rb, -(CH2)p-S(O)2Rb, -(CH2)p-S(O)2NRcRd, -(CH2)p-SO2ORb, -(CH2)p-CO2Rb, -(CH2)p-CONRcRd, -(CH2)p-CSNRcRd, - (CH2)p-ORb, -(CH2)p-SRb, -(CH2)p-CRb(OH)-Re, -(CH2)p-C=NORb, -O-(CH2)n-O-, -O-(CH2)n-CH2-, -O-CH=CH- o -(CH2)n+2-, en donde es n = 1 o 2 y los átomos de O y/o átomos de C están unidos con átomos de C del anillo directamente adyacentes o A es un radical -CO2Rb, C(O)NRcRd, CORb, o A es un grupo alquenilo -CR5=CR6R7, en donde R5, R6 y R7 son iguales o diferentes y, de modo independiente entre sí, son átomo de H, átomos de halogeno, radicales arilo o un grupo alquilo C1-5 no sustituido o parcial o totalmente fluorado o A es un grupo alquinilo -C:::CR5, con el significado indicado arriba para R5 y B es un grupo carbonilo o un grupo CH2, así como sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005030294A DE102005030294A1 (de) | 2005-06-24 | 2005-06-24 | Nichtsteroidale Progesteronrezeptor-Modulatoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057409A1 true AR057409A1 (es) | 2007-12-05 |
Family
ID=36716643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102752A AR057409A1 (es) | 2005-06-24 | 2006-06-27 | Heterociclos oxigenados como moduladores de receptores de progesterona. composiciones farmaceuticas. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1899315A1 (es) |
| JP (1) | JP2008543911A (es) |
| KR (1) | KR20080018275A (es) |
| CN (1) | CN101248056A (es) |
| AR (1) | AR057409A1 (es) |
| AU (1) | AU2006261049A1 (es) |
| BR (1) | BRPI0612305A2 (es) |
| CA (1) | CA2611900A1 (es) |
| CR (1) | CR9595A (es) |
| DE (1) | DE102005030294A1 (es) |
| DO (1) | DOP2006000150A (es) |
| EA (1) | EA200702604A1 (es) |
| EC (1) | ECSP078043A (es) |
| GT (1) | GT200600272A (es) |
| IL (1) | IL188022A0 (es) |
| MX (1) | MX2008000070A (es) |
| NO (1) | NO20080441L (es) |
| PE (1) | PE20070170A1 (es) |
| TW (1) | TW200738665A (es) |
| UY (1) | UY29626A1 (es) |
| WO (1) | WO2006136462A1 (es) |
| ZA (1) | ZA200800689B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY30805A1 (es) * | 2006-12-21 | 2008-07-31 | Bayer Schering Pharma Ag | Moduladores no esteroides de receptores de progesterona |
| DE102007032800A1 (de) * | 2007-07-10 | 2009-01-15 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| DE102007058747A1 (de) | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| EP2854763B1 (en) | 2012-05-31 | 2018-09-26 | Repros Therapeutics Inc. | Formulations for vaginal delivery of antiprogestins |
| JP6343619B2 (ja) | 2012-11-02 | 2018-06-13 | レプロス セラピューティクス インコーポレイティド | プロゲステロン依存性病態を処置する方法およびその組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19723722A1 (de) * | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| WO2000066590A2 (en) * | 1999-05-04 | 2000-11-09 | Ligand Pharmaceuticals, Inc. | Tetracyclic progesterone receptor modulator compounds and methods |
| US6358948B1 (en) * | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| WO2003059899A1 (en) * | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| RS89504A (sr) * | 2002-03-11 | 2006-10-27 | Schering Ag. | 5-(2-hidroksi-3-/1-(3-trifluormetilfenil)-ciklopropil/- propionilamino)-ftalid i srodna jedinjenja koja imaju modulirajuću aktivnost na progesteron receptor za upotrebu kod kontrole plodnosti i terapije izmene hormona |
| DE10346939A1 (de) * | 2003-10-06 | 2005-05-19 | Schering Ag | Heterocyclisch substituierte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
-
2005
- 2005-06-24 DE DE102005030294A patent/DE102005030294A1/de not_active Ceased
-
2006
- 2006-06-22 BR BRPI0612305-8A patent/BRPI0612305A2/pt not_active Application Discontinuation
- 2006-06-22 AU AU2006261049A patent/AU2006261049A1/en not_active Abandoned
- 2006-06-22 KR KR1020087001789A patent/KR20080018275A/ko not_active Withdrawn
- 2006-06-22 CA CA002611900A patent/CA2611900A1/en not_active Abandoned
- 2006-06-22 EA EA200702604A patent/EA200702604A1/ru unknown
- 2006-06-22 WO PCT/EP2006/006532 patent/WO2006136462A1/en not_active Ceased
- 2006-06-22 CN CNA2006800306699A patent/CN101248056A/zh active Pending
- 2006-06-22 EP EP06762405A patent/EP1899315A1/en not_active Withdrawn
- 2006-06-22 MX MX2008000070A patent/MX2008000070A/es not_active Application Discontinuation
- 2006-06-22 JP JP2008517445A patent/JP2008543911A/ja active Pending
- 2006-06-23 TW TW095122741A patent/TW200738665A/zh unknown
- 2006-06-26 UY UY29626A patent/UY29626A1/es not_active Application Discontinuation
- 2006-06-26 DO DO2006000150A patent/DOP2006000150A/es unknown
- 2006-06-26 PE PE2006000732A patent/PE20070170A1/es not_active Application Discontinuation
- 2006-06-26 GT GT200600272A patent/GT200600272A/es unknown
- 2006-06-27 AR ARP060102752A patent/AR057409A1/es unknown
-
2007
- 2007-12-10 IL IL188022A patent/IL188022A0/en unknown
- 2007-12-14 CR CR9595A patent/CR9595A/es not_active Application Discontinuation
- 2007-12-21 EC EC2007008043A patent/ECSP078043A/es unknown
-
2008
- 2008-01-23 NO NO20080441A patent/NO20080441L/no not_active Application Discontinuation
- 2008-01-23 ZA ZA200800689A patent/ZA200800689B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008543911A (ja) | 2008-12-04 |
| KR20080018275A (ko) | 2008-02-27 |
| BRPI0612305A2 (pt) | 2010-11-03 |
| WO2006136462A1 (en) | 2006-12-28 |
| PE20070170A1 (es) | 2007-03-02 |
| AU2006261049A1 (en) | 2006-12-28 |
| ECSP078043A (es) | 2008-01-23 |
| ZA200800689B (en) | 2009-07-29 |
| UY29626A1 (es) | 2007-01-31 |
| CN101248056A (zh) | 2008-08-20 |
| CR9595A (es) | 2008-05-05 |
| EP1899315A1 (en) | 2008-03-19 |
| DOP2006000150A (es) | 2006-12-31 |
| EA200702604A1 (ru) | 2008-06-30 |
| CA2611900A1 (en) | 2006-12-28 |
| MX2008000070A (es) | 2008-03-19 |
| NO20080441L (no) | 2008-03-07 |
| GT200600272A (es) | 2007-08-20 |
| IL188022A0 (en) | 2008-03-20 |
| DE102005030294A1 (de) | 2007-01-04 |
| TW200738665A (en) | 2007-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030306A1 (es) | Derivados de piperazina, un procedimiento para su preparacion, composiciones farmaceuticas, un metodo para su fabricacion y el uso de dichos derivados para la fabricacion de un medicamento | |
| AR035305A1 (es) | Derivados y analogos del acido 3-arilpropionico, proceso para su preparacion, formulaciones farmaceuticas, uso de los mismos en la elaboracion de medicamentos, y formulacion farmaceutica para usar en la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| PE20080988A1 (es) | Compuestos triciclicos fusionados de sulfonamida como inhibidores de gama-secretasa | |
| AR064547A1 (es) | Derivados de azaspiro como antagonistas del receptor v1a | |
| AR062695A1 (es) | N-(1- ftalazin -1--il- piperidin -4-il) - amidas como moduladores del receptor ep2 | |
| AR081859A1 (es) | Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr | |
| PA8517101A1 (es) | Derivados de tropano ùtiles en terapia | |
| AR035517A1 (es) | Derivados de piperazina, proceso para prepararlos, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la elaboracion de medicamentos | |
| DOP2007000018A (es) | Moduladores de indol sulfonamida de receptores de progesterona | |
| AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
| PE20200665A1 (es) | Compuestos espirociclicos y sus metodos de preparacion y uso | |
| UY27978A1 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
| ECSP088293A (es) | Inhibidores de gamma secretasa, de sulfonamido n-cíclico puenteado | |
| BR112015032637A2 (pt) | derivados de pirrolopiridina ou pirazolopiridina | |
| UY27983A1 (es) | Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| CO6260069A2 (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa | |
| PE20091436A1 (es) | Derivados de sulfonamidas sustituidas como moduladores b1r | |
| AR067075A1 (es) | Derivados de isoxasol - imidazol | |
| CO2019002673A2 (es) | Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso | |
| PE20081113A1 (es) | Inhibidores virales policiclicos | |
| AR066604A1 (es) | Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente. | |
| AR052549A1 (es) | Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2 | |
| DOP2013000306A (es) | Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |